Retrospective analysis of visceral leishmaniasis relapses in immunocompetent patients who received treatment with 20mg/kg liposomal amphotericin B in Bihar, India

摘要

Background: India reportedly has 70% of the worldwide burden of Visceral Leishmaniasis(VL), with Bihar having 90% of reported cases. With the support of the RMRI, MSF has implemented a VL treatment project in Vaishali district, endemic for Leishmania donovani, using total dose 20mg/Kg liposomal amphotericin-B(L-AmB) as the first-line drug.